Kamada (KMDA) Operating Expenses (2012 - 2026)
Kamada's (KMDA) quarterly Operating Expenses came in at -$13.0 million in Q2 2026, down 9.27% on a YoY basis from -$14.3 million in Q2 2025, and down 6.53% quarter-over-quarter from -$12.2 million in Q1 2026.
Analysis
Kamada (KMDA) Operating Expenses (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Operating Expenses for 15 consecutive years, with -$13.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Expenses fell 9.27% year-over-year to -$13.0 million; the trailing twelve-month figure through Jun 2026 stood at -$5.3 million (up 79.85% YoY), and the FY2025 full-year result was -$50.2 million, down 213.76% from the prior year.
- Operating Expenses fell to -$13.0 million in Q2 2026 per KMDA's latest filing, from -$12.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $12.3 million in Q4 2025 and bottomed at -$13.0 million in Q2 2026.
- Historically, Operating Expenses has averaged $505888.9 across 5 years, with a median of $6.5 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses sank 266.08% in 2023, then surged 188.58% in 2024.
- Over 5 years, Operating Expenses stood at $9.3 million in 2022, then slumped by 224.78% to -$11.6 million in 2023, then soared by 188.58% to $10.3 million in 2024, then rose by 19.69% to $12.3 million in 2025, then tumbled by 205.03% to -$13.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered -$13.0 million, -$12.2 million, and $12.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn | -12.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.96 Mn |
| Mar 31, 2026 | -12.16 Mn |
| Dec 31, 2025 | 12.34 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Jun 30, 2025 | -11.86 Mn |
| Mar 31, 2025 | -12.95 Mn |
| Dec 31, 2024 | 10.31 Mn |
| Sep 30, 2024 | -11.94 Mn |
| Jun 30, 2024 | 8.58 Mn |
| Mar 31, 2024 | 8.08 Mn |
| Dec 31, 2023 | -11.64 Mn |
| Sep 30, 2023 | -10.44 Mn |
| Jun 30, 2023 | 7.77 Mn |
| Mar 31, 2023 | 6.65 Mn |
| Dec 31, 2022 | 9.33 Mn |
| Sep 30, 2022 | 6.28 Mn |
| Jun 30, 2022 | 5.95 Mn |
| Mar 31, 2022 | 10.31 Mn |
| Dec 31, 2021 | 9.28 Mn |
| Sep 30, 2021 | 5.24 Mn |